MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
ROCKVILLE, MD, May 10, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, today announced financial results for the first quarter ended March 31, 2023, and updated 2023 revenue guidance.
First Quarter Highlights
“Given the evolving operating environment, we are pleased with our first quarter results and the progress we have made towards delivering on our long-term financial and strategic initiatives,” said Doug Doerfler, President and CEO of MaxCyte. “2023 continues to develop into a challenging year for the industry, as companies prioritize their internal development assets within an evolving funding environment, and we are updating our guidance accordingly. We continue to make important progress in 2023, highlighted by expanding our partnership portfolio with two new partners announced including Walking Fish Therapeutics in May and Catamaran Bio in January. Our partnership pipeline continues to develop, with a number of potential partners operating across a variety of cell types, indications, and gene-editing modalities.
“We also look forward to a potentially first commercially approved product enabled by our platform, Vertex and CRISPR’s exa-cel program, which recently announced completion of their rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for sickle cell disease and transfusion-dependent beta thalassemia with request for Priority Review. MaxCyte’s technology continues to play a key role enabling the development of lifesaving therapeutics across various disease types. We are excited to see our partners’ progress in 2023 and beyond as the cell therapy industry moves forward.”
1
The following table provides details regarding the sources of our revenue for the periods presented.
| | Three Months Ended |
|
| | ||||
| | March 31, (Unaudited) | | | | ||||
|
| 2023 |
| 2022 |
| % | | ||
(in thousands, except percentages) | |
| | |
| | |
| |
Cell therapy | | $ | 5,975 | | $ | 7,416 | | (19%) | |
Drug discovery | |
| 1,797 | |
| 2,167 | | (17%) | |
Program-related | |
| 804 | |
| 2,004 | | (60%) | |
Total revenue | | $ | 8,576 | | $ | 11,587 | | (26%) | |
First Quarter 2023 Financial Results
Total revenue for the first quarter of 2023 was $8.6 million, compared to $11.6 million in the first quarter of 2022, representing a decline of 26%.
Core business revenue (sales and leases of instruments and disposables to cell therapy and drug discovery customers but excluding program-related revenue) for the first quarter of 2023 was $7.8 million, compared to $9.6 million in the first quarter of 2022, representing a decline of 19%.
Cell therapy revenue for the first quarter of 2023 was $6.0 million, compared to $7.4 million in the first quarter of 2022, representing a decline of 19%. Drug discovery revenue for the first quarter was $1.8 million, compared to $2.2 million in the first quarter 2022, representing a decline of 17%.
SPL program-related revenue was $0.8 million in the first quarter of 2023 as compared to $2.0 million SPL program-related revenue in the first quarter of 2022.
Gross profit for the first quarter of 2023 was $7.6 million (88% gross margin), compared to $10.5 million (91% gross margin) in the first quarter of 2022.
Operating expenses for the first quarter of 2023 were $20.8 million, compared to operating expenses of $14.7 million in the first quarter of 2022.
First quarter 2023 net loss was $10.9 million compared to net loss of $4.1 million for the same period in 2022. EBITDA, a non-GAAP measure, was a loss of $12.2 million for the first quarter of 2023, compared to a loss of $3.7 million for the first quarter of 2022. Stock-based compensation expense was $3.3 million in the first quarter of 2023 compared to $2.5 million in the first quarter of 2022.
2023 Revenue Guidance
We now expect total revenue for 2023 to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10% and Strategic Platform License (“SPL”) program-related revenue expectations remaining the same at approximately $6 million for the year.
2
Webcast and Conference Call Details
MaxCyte will host a conference call today, May 10, 2023, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.
Non-GAAP Financial Measures
This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses this non-GAAP measure to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.
Management does not consider EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of EBITDA is that it excludes significant expenses that are required by GAAP to be recorded in the company’s financial statements. In order to compensate for these limitations, management presents EBITDA together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of net loss, the most comparable GAAP financial measure, to EBITDA is included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements
3
regarding expected total revenue growth, core business revenue growth and SPL program-related revenue for the year ending December 31, 2023, expansion of and revenue from our SPLs and the progression of our customers’ programs into and through clinical trials. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with the timing of our customers’ ongoing and planned clinical trials; the adequacy of our cash resources and availability of financing on commercially reasonable terms; general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and demand for our products. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 15, 2023, as well as in discussions of potential risks, uncertainties, and other important factors in our most recent Quarterly report on Form 10-Q and the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements represent our views only as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Seismic Collaborative, A Spectrum Science Company
Valerie Enes
+1 408-497-8568
valerie@teamseismic.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
4
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Unaudited Condensed Consolidated Balance Sheets
| | March 31, | | December 31, | ||
|
| 2023 |
| 2022 | ||
| | | | | | |
Assets |
| | | | | |
Current assets: |
| |
|
| |
|
Cash and cash equivalents | | $ | 37,833,400 | | $ | 11,064,700 |
Short-term investments, at amortized cost | |
| 186,819,300 | |
| 216,274,900 |
Accounts receivable | |
| 8,294,800 | |
| 11,654,600 |
Accounts receivable - TIA (Note 7) | | | 996,600 | | | 1,912,400 |
Inventory | |
| 10,264,900 | |
| 8,580,800 |
Prepaid expenses and other current assets | |
| 2,230,600 | |
| 2,778,800 |
Total current assets | |
| 246,439,600 | |
| 252,266,200 |
| | | | | | |
Property and equipment, net | | | 24,947,900 | |
| 23,724,700 |
Right of use asset - operating leases | |
| 9,757,600 | |
| 9,853,500 |
Other assets | |
| 399,300 | |
| 809,000 |
Total assets | | $ | 281,544,400 | | $ | 286,653,400 |
| | | | | | |
Liabilities and stockholders’ equity | |
|
| |
|
|
Current liabilities: | |
|
| |
|
|
Accounts payable | | $ | 3,502,100 | | $ | 531,800 |
Accrued expenses and other | |
| 6,912,900 | |
| 8,025,300 |
Operating lease liability, current | |
| 475,200 | |
| 156,800 |
Deferred revenue, current portion | |
| 5,749,200 | |
| 6,712,600 |
Total current liabilities | |
| 16,639,400 | |
| 15,426,500 |
| | | | | | |
Operating lease liability, net of current portion | |
| 15,777,200 | |
| 15,938,100 |
Other liabilities | |
| 1,309,000 | |
| 1,321,600 |
Total liabilities | |
| 33,725,600 | |
| 32,686,200 |
| | | | | | |
| |
|
| |
|
|
Stockholders’ equity | |
|
| |
|
|
Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2023 and December 31, 2022 | | | — | | | — |
Common stock, $0.01 par value; 400,000,000 shares authorized, 102,904,745 and 102,397,913 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | | | 1,029,100 | | | 1,024,000 |
Additional paid-in capital | |
| 395,546,600 | |
| 390,818,500 |
Accumulated deficit | |
| (148,756,900) | |
| (137,875,300) |
Total stockholders’ equity | |
| 247,818,800 | |
| 253,967,200 |
Total liabilities and stockholders’ equity | | $ | 281,544,400 | | $ | 286,653,400 |
5
MaxCyte, Inc.
Unaudited Condensed Consolidated Statements of Operations
| | Three Months Ended March 31, | | ||||
|
| 2023 |
| 2022 | | ||
Revenue | | $ | 8,576,300 | | $ | 11,587,300 | |
Cost of goods sold | |
| 999,800 | |
| 1,062,600 | |
Gross profit | |
| 7,576,500 | |
| 10,524,700 | |
| | | | | | | |
Operating expenses: | |
|
| |
|
| |
Research and development | |
| 6,046,500 | |
| 3,765,300 | |
Sales and marketing | |
| 6,296,100 | |
| 3,838,700 | |
General and administrative | |
| 7,498,900 | |
| 6,632,500 | |
Depreciation and amortization | | | 912,200 | | | 447,300 | |
Total operating expenses | |
| 20,753,700 | |
| 14,683,800 | |
Operating loss | |
| (13,177,200) | |
| (4,159,100) | |
| | | | | | | |
Other income (expense): | |
|
| |
|
| |
Interest income | | | 2,295,600 | | | 91,800 | |
Total other income (expense) | |
| 2,295,600 | |
| 91,800 | |
Net loss | | $ | (10,881,600) | | $ | (4,067,300) | |
Basic and diluted net loss per share | | $ | (0.11) | | $ | (0.04) | |
Weighted average shares outstanding, basic and diluted | |
| 102,846,036 | |
| 101,305,943 | |
6
MaxCyte, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
|
| Three Months Ended March 31, | |||||
| | 2023 |
| 2022 |
| ||
Cash flows from operating activities: |
| |
|
| |
|
|
Net loss | | $ | (10,881,600) | | $ | (4,067,300) | |
| | | | | | | |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | |
| | |
Depreciation and amortization | |
| 961,700 | |
| 487,400 | |
Net book value of consigned equipment sold | |
| 16,800 | |
| 32,800 | |
Stock-based compensation | |
| 3,276,600 | |
| 2,462,400 | |
Amortization of discounts on short-term investments | |
| (1,730,100) | |
| (33,200) | |
| | | | | | | |
Changes in operating assets and liabilities: | |
| | |
| | |
Accounts receivable | |
| 3,359,800 | |
| (1,750,800) | |
Accounts receivable - TIA | | | 915,800 | | | (2,119,200) | |
Inventory | |
| (1,706,000) | |
| (1,377,000) | |
Prepaid expense and other current assets | |
| 548,200 | |
| 1,117,200 | |
Right of use asset – operating leases | |
| 95,900 | |
| (5,212,600) | |
Other assets | |
| 409,700 | |
| (738,200) | |
Accounts payable, accrued expenses and other | |
| 1,227,000 | |
| (150,500) | |
Operating lease liability | |
| 157,500 | |
| 7,569,000 | |
Deferred revenue | |
| (963,400) | |
| 84,900 | |
Other liabilities | |
| (12,600) | |
| 900 | |
Net cash used in operating activities | |
| (4,324,700) | |
| (3,694,200) | |
| | | | | | | |
Cash flows from investing activities: | |
|
| |
|
| |
Purchases of short-term investments | |
| (57,814,300) | | | — | |
Maturities of short-term investments | |
| 89,000,000 | | | 200,796,000 | |
Purchases of property and equipment | |
| (1,558,000) | | | (5,999,500) | |
Proceeds from sale of equipment | | | 9,100 | | | — | |
Net cash provided by investing activities | |
| 29,636,800 | |
| 194,796,500 | |
| | | | | | | |
Cash flows from financing activities: | |
|
| |
|
| |
Proceeds from exercise of stock options | |
| 1,456,600 | | | 892,600 | |
Net cash provided by financing activities | |
| 1,456,600 | |
| 892,600 | |
Net increase in cash and cash equivalents | |
| 26,768,700 | |
| 191,994,900 | |
Cash and cash equivalents, beginning of period | |
| 11,064,700 | |
| 47,782,400 | |
Cash and cash equivalents, end of period | | $ | 37,833,400 | | $ | 239,777,300 | |
7
Unaudited Reconciliation of Net Loss (GAAP) to EBITDA (Non-GAAP)
| Three Months Ended | ||||||
| March 31, | ||||||
| 2023 |
| 2022 | ||||
(in thousands) | |
|
| |
| ||
Net loss (GAAP) | $ | (10,882) | | $ | (4,067) | ||
Depreciation and amortization expense | | 962 | | | 487 | ||
Interest income |
| (2,296) | |
| (92) | ||
Income taxes |
| — | |
| — | ||
EBITDA (Non-GAAP) | $ | (12,216) | | $ | (3,672) | ||
8